Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Trial ID or NCT#
NCT00136084
Status
NOT RECRUITING
Purpose
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Official Title
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Eligibility Criteria
Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical staining; myelodysplasia; or biphenotypic leukemia. - Age less than or equal to 21 years at time of study entry. - No prior therapy for this malignancy (patients with secondary AML following treatment of primary malignancy are eligible) except for one dose of intrathecal therapy. - Negative pregnancy test - Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)
Exclusion Criteria:
- - Positive pregnancy test - Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)
Investigator(s)
Gary Dahl
Contact us to find out if this trial is right for you.
Contact
LPCH New Patient Coordinator
6507251072
View on ClinicalTrials.gov
